PURAPHARM CORPORATION LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.75 HKD | 0.00% |
|
0.00% | -16.67% |
| 01/04 | PuraPharm's Net Loss Shrinks in 2023; Revenue Falls 9% | MT |
| 28/03 | PuraPharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2021 | 660M 84.26M 7.03B | Sales 2022 | 448M 57.24M 4.77B | Capitalization | 506M 64.6M 5.39B |
|---|---|---|---|---|---|
| Net income 2021 | -122M -15.58M -1.3B | Net income 2022 | -120M -15.33M -1.28B | EV / Sales 2021 | 1.14 x |
| Net Debt 2021 | 436M 55.68M 4.64B | Net Debt 2022 | 427M 54.59M 4.55B | EV / Sales 2022 | 2.08 x |
| P/E ratio 2021 |
-2.62
x | P/E ratio 2022 |
-4.2
x | Employees | 662 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 47.06% |
More Fundamentals
* Assessed data
More news
More press releases
| Current month | -9.64% | ||
| 1 month | -7.41% | ||
| 3 months | -7.41% | ||
| 6 months | -25.00% | ||
| Current year | -16.67% |
1 week
0.74
0.78
1 month
0.730.89
Current year
0.730.95
1 year
0.731.26
3 years
0.662.00
5 years
0.562.74
10 years
0.565.90
| Managers | Title | Age | Since |
|---|---|---|---|
Yu Ling Chan
CEO | Chief Executive Officer | 63 | 05/98/05 |
Hang Woon Ma
SAM | Sales & Marketing | - | - |
Pui Hung
HRO | Human Resources Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kwok Wah Ho
BRD | Director/Board Member | 65 | 12/15/12 |
Lim Kin Leung
BRD | Director/Board Member | 70 | 12/15/12 |
Yu Ling Chan
CEO | Chief Executive Officer | 63 | 05/98/05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 0.75 | 0.00% | 70,000 |
| 25/24/25 | 0.75 | 0.00% | 0 |
| 24/24/24 | 0.75 | +1.35% | 208,000 |
| 23/24/23 | 0.74 | -1.33% | 83,500 |
| 22/24/22 | 0.75 | 0.00% | 136,000 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 01:38 pm IST
More quotes
PuraPharm Corporation Ltd is an investment holding company principally engaged in the concentrated Chinese medicine granule (CCMG) businesses. The Company operates through five business segments. The China CCMG segment is mainly engaged in the production and sales of CCMG products in China. The Hong Kong CCMG segment is mainly engaged in the sales of CCMG products, excluding the sales through self-operated clinics in Hong Kong. The Chinese Healthcare Products segment is mainly engaged in the production and sales of healthcare products in Hong Kong and China. The Clinics segment is mainly engaged in the provision of Chinese medical diagnostic services and sales of CCMG products through self-operated clinics. The Plantation segment is mainly engaged in the plantation and trading of raw Chinese herbs, and the manufacture and sale of traditional Chinese medicine (TCM) decoction pieces.
Sector
Pharmaceuticals
Calendar
27/08/2024
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -16.67% | 37.85M | |
| +35.04% | 5.92B | |
| -15.13% | 4.51B | |
| -9.75% | 3.15B | |
| +2.14% | 3.1B | |
| -6.82% | 2.42B | |
| +47.87% | 1.97B | |
| -7.89% | 1.68B | |
| +0.09% | 1.65B | |
| -12.97% | 1.53B |
- Stock Market
- Equities
- 1498 Stock
